聖湘生物(688289.SH):擬投資認購蘇州金闔二期股權投資合夥企業(有限合夥)份額 投向生物技術等相關領域
格隆匯 9 月 17日丨聖湘生物(688289.SH)公佈,公司擬作為有限合夥人與廣州金垣坤通股權投資管理有限公司(“金垣坤通”)及其他出資方共同投資產業投資基金蘇州金闔二期股權投資合夥企業(有限合夥)(“投資基金”或“合夥企業”)。投資範圍為醫療器械、醫療服務、生物技術相關領域。投資基金目標募集規模為人民幣15億元,初始已認繳出資總額為人民幣5.4億元,公司以自有資金擬認繳合夥企業的出資金額為人民幣1億元。
合夥企業的投資領域為醫療器械、醫療服務、生物技術相關領域,公司通過項目投資實現資本增值,並將進一步推動公司在體外診斷領域業務的擴展及產業鏈延伸,為公司的長期戰略發展目標服務,提升核心競爭力。
交易完成後,該合夥企業不會納入公司的合併報表範圍。公司此次參與投資產業基金資金來源於自有資金,不會影響公司生產經營活動的正常運行,不會對公司2020年度財務及經營狀況產生重大影響,不存在損害上市公司及全體股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.